{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:17:36Z","timestamp":1769228256588,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["15lk0201019h0003"],"award-info":[{"award-number":["15lk0201019h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.vaccine.2018.05.009","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T12:57:52Z","timestamp":1525525072000},"page":"3423-3426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFN\u03b3-producing cells"],"prefix":"10.1016","volume":"36","author":[{"given":"Atsushi","family":"Komatsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizunobu","family":"Igimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Kawana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.009_b0005","doi-asserted-by":"crossref","unstructured":"zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2(5):342\u201350.","DOI":"10.1038\/nrc798"},{"issue":"8","key":"10.1016\/j.vaccine.2018.05.009_b0010","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States","volume":"297","author":"Ef","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.05.009_b0015","doi-asserted-by":"crossref","unstructured":"Bosch FX, de Sanjos\u00e9 S. Chapter 1: Human papillomavirus and cervical cancer\u2014burden and assessment of causality. JNCI Monogr 2003;2003(31):3\u201313.","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.009_b0020","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.AOG.0000110246.93627.17","article-title":"ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial","volume":"103","author":"Garcia","year":"2004","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.vaccine.2018.05.009_b0025","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Hern\u00e1ndez E, Gonz\u00e1lez-S\u00e1nchez JL, Andrade-Manzano A, Contreras ML, Padilla S, Guzm\u00e1n CC, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006;13(6):592\u20137.","DOI":"10.1038\/sj.cgt.7700937"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.009_b0030","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/ijgc-00009577-200605000-00020","article-title":"Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial","volume":"16","author":"Fiander","year":"2006","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.009_b0035","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2007.05.038","article-title":"A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia","volume":"106","author":"Roman","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.009_b0040","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ygyno.2007.04.038","article-title":"Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III","volume":"106","author":"Einstein","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2018.05.009_b0045","doi-asserted-by":"crossref","unstructured":"Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+Cervical intraepithelial neoplasia 2\/3. Clin Cancer Res 2009;15(1):361\u20137.","DOI":"10.1158\/1078-0432.CCR-08-1725"},{"issue":"11","key":"10.1016\/j.vaccine.2018.05.009_b0050","first-page":"3356","article-title":"A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix","volume":"7","author":"Follen","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2018.05.009_b0055","doi-asserted-by":"crossref","unstructured":"Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, et al. Immunotherapy against HPV16\/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012;4(155):155ra138\u2013155ra138.","DOI":"10.1126\/scitranslmed.3004414"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.009_b0060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1600-0897.2011.01041.x","article-title":"Characterization of gut-derived intraepithelial lymphocyte (IEL) residing in human papillomavirus (HPV)-infected intraepithelial neoplastic lesions","volume":"66","author":"Kojima","year":"2011","journal-title":"Am J Reprod Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2018.05.009_b0065","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2174\/156652409789105525","article-title":"Role of beta7 integrins in intestinal lymphocyte homing and retention","volume":"9","author":"Gorfu","year":"2009","journal-title":"Curr Mol Med"},{"issue":"47","key":"10.1016\/j.vaccine.2018.05.009_b0070","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1016\/j.vaccine.2014.09.020","article-title":"Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients","volume":"32","author":"Kawana","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.009_b0075","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2174\/1874357901206010264","article-title":"Therapeutic human papillomavirus (HPV) vaccines: a novel approach","volume":"6","author":"Kawana","year":"2012","journal-title":"Open Virol J"},{"issue":"16","key":"10.1016\/j.vaccine.2018.05.009_b0080","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1016\/j.vaccine.2010.02.005","article-title":"Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7","volume":"28","author":"Adachi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.009_b0085","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1016\/j.vaccine.2012.06.027","article-title":"Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune response to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner","volume":"30","author":"Taguchi","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.009_b0090","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4014\/jmb.0907.07032","article-title":"Development of a highly efficient protein-secreting system in recombinant Lactobacillus casei","volume":"20","author":"Kajikawa","year":"2010","journal-title":"J Microbiol Biotechnol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T16:36:25Z","timestamp":1604248585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18306157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":18,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0264410X18306157"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFN\u03b3-producing cells","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}